The IMID Forum

The Immune-Mediated Inflammatory Disease Forum

Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.

  1. Author Interview: Doctor David Kellner, September 2025

    4 DAYS AGO

    Author Interview: Doctor David Kellner, September 2025

    Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor David Kellner, an IGNITE-MSCR Fellow of the Division of Rheumatology, from UCLA Medical Centre, LA, USA, as they discuss his recent review ‘Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis’.

    23 min
  2. Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases

    25 SEPT

    Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases

    Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he highlights two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-TNFα.

    9 min
  3. Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA

    18 SEPT

    Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA

    Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the effectiveness of ixekizumab in real-world patients with axSpA and PsA, and the real‑world comparison of clinical effectiveness of UPA, TNF inhibitors or IL‑17 inhibitors in patients with axSpA after switching from an initial TNF inhibitor.

    21 min

  4. 4 SEPT

    Discussing RA: Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis

    Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month’s discussion covered the ‘Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis’. Read the full paper summary online at www.imidforum.com.

    8 min
  5. Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025

    28 AUG

    Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025

    Join Professor Peter Nash from Griffith University in Brisbane, and Dr Rodrigo Garcia‑Salinas from Hospital Italiano de La Plata in Argentina, as they discuss Dr Garcia-Salinas’ recent publication ‘Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns’.

    29 min
  6. Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025

    14 AUG

    Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025

    Join Professor Peter Nash from the Griffith University in Brisbane, and authors Dr Martin Schaefer from the German Rheumatology Research Center in Berlin, Germany and Professor Anja Strangfeld, the head of epidemiology at the German Rheumatology Research Centre. In this episode they discuss a recent study from the German RABBIT registry, investigating the comparative risk of malignancies in rheumatoid arthritis patients treated with JAK inhibitors versus bDMARDs.

    45 min
  7. Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials

    7 AUG

    Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials

    Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the influence of csDMARDs use on efficacy and safety of deucravacitinib in pateints with PsA’ and ‘the incidence rate of uveitis in patients with axSpA and PsA treated with secukinumab’.

    18 min
  8. Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting

    31 JUL

    Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting

    Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month, the conversation covered the ‘dual JAK and ROCK inhibition with CPL’116 in patients with RA with inadequate response to MTX’ and ‘the benefit–risk analysis of UPA versus adalimumab in patients with RA and higher or lower risk of cardiovascular disease’

    13 min
See All (371)

About

Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.

Information

  • Creator
    The Immune-Mediated Inflammatory Disease Forum
  • Years Active
    2015 - 2025
  • Episodes
    371
  • Rating
    Clean
  • Copyright
    © All rights reserved
  • Show Website
    The IMID Forum

You Might Also Like